APP and Dravet syndrome: This new class of APP translation inhibitors may, in fact, be considered most suitable to treat the orphan disease of APP-trisomy that causes the Dup–APP (hemorrhagic AD) as a form of fAD and also for cases of amyloidosis with complications in DS patients over 40 years of age.